Back to trial details

Intake questionnaire

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Applying to Northwest Georgia Oncology Centers /ID# 275374 · Marietta, Georgia

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Non-Small Cell Lung Cancer?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Marietta for study visits?